Precision Medicine in ER-Positive Metastatic Breast Cancer

The chapter explores progression-free survival and AKT pathway alterations in ER-positive metastatic breast cancer, highlighting the impact of genetic mutations on treatment effectiveness and toxicity. It emphasizes the importance of understanding specific mutations like PIC-3CA and ESR1 for personalized therapy in the evolving landscape of precision medicine.